Skip to main content
You have permission to edit this article.
Neustatter: Are pharmacy benefit managers operating a big shell game?

Neustatter: Are pharmacy benefit managers operating a big shell game?

  • 0

You’re probably sick of reading about COVID-19, and all the ways it can stress you out. So, instead, let me bring to your attention a different health care issue for you to fret about.

It’s an issue that epitomizes the way health care is being taken over by business entities whose priority is to make money more than to provide effective affordable health care to the people it is serving.

I’m talking about pharmacy benefit managers—PBMs.

Growing Awareness

I have been aware of these third-party administrators of prescription drug programs for awhile. I had heard rumors they were driving up drug prices. But my vague notions were solidified by reading “The Price We Pay: What Broke American Healthcare—and How We Fix it” by Dr. Marty Makary.

Makary is a surgeon at Johns Hopkins, and was the lead author of a report in JAMA in 2017 about hospitals suing patients for outstanding medical bills. You may have read about him when he came to Fredericksburg and advised patients being taken to court by Mary Washington Healthcare in 2019.

Pharmacy benefits managers started off innocently enough, administering the complex formularies of insurance companies and self-insured employers. They negotiate with drug companies, decide what tier a medicine should be in, and determine how much someone insured through that company would pay. They have great potential to keep drug prices down by negotiating bulk-buy discounts, or rebates from the drug manufacturers.

Medications are a large and profitable part of health care, and now PBMs seem to have taken on a life of their own—but by using devious practices to make massive profits.

Makary says, “It is now overwhelmingly apparent that PBMs are operating the biggest shell game in modern history, and we are all paying for it.”

How it Works

PBMs buy medicines at a discounted price, then “sell” them (actually they arrange the price at which they will be sold) at a markup, which they get paid by the insurance company or employer whose formulary they are managing—what is called “the spread” rather than profit, in this industry.

They also get drug manufacturers to pay them a rebate to get their drug on any formulary they manage—which, of course,, increases the sale of the medicine. But then, apparently, the drug manufacturer increases the price of the drug to offset that rebate.

What makes it all so devious is that the size of the spread, and a lot of other stuff about their doings, is a closely guarded secret. No one knows how much they’re marking up your medicine.

Also until recently, they had gag clauses in their contracts with pharmacists. This meant the pharmacist wasn’t allowed to spontaneously tell someone if it would be cheaper to buy the medicine not through their insurance plan—though there are now laws making gag clauses illegal.

Nonetheless, PBMs are gaining market share. Over 80 percent of pharmaceuticals in the United States are purchased through PBM networks. And, presumably from seeing what a good business this can be, insurance companies are buying up the PBMs.

The “big three” are OptumRx, which is now owned by United Health Group; CVS Caremark, which is merging with Aetna; and Express Scripts, the largest, with a revenue of $155 billion for 2020. Express Scripts was just bought by Cigna, in December 2018 for $67 billion. It captures 78 percent of the market.

These mergers have the added disadvantage that when the insurance company, PBM and pharmacy are all one entity, it creates a conflict of interests because they make more money if consumers buy more expensive drugs.

Consumer Reports did a “secret shopper” investigation to check drug prices by calling pharmacies, asking their combined retail cash price for five common drugs. The batch of five drugs was just $66 online at, but national retailers CVS and Rite Aid priced them at almost $900.

Another example is the antidepressant Cymbalta. It cost $22 at an independent pharmacy and $251 at Walgreens. I’ve experienced the same. Walmart wanted $60 for 30 pills of pantoprazole, which I got for $8.95 from Blink Health.

Incidentally, Consumer Reports recommends Blink Health, but also GoodRx, and

Another Issue for Our Legislators

Drug prices are out of control, and PBMs seem to have a lot to do with it. The watchdog organization says “pharmacy benefit managers are one of the most problematic, least regulated and least understood aspects of the health care delivery system.”

You can fight back against overpriced medicines by shopping around. But restraining PBMs is another of those issues legislators need to take up. (I feel like that is my solution to so many of the health care madness issues I write about, but it’s true.)

Maybe we can go beyond mere PBMs, also? Maybe we can spur our legislators to reform all this hedge fund/Wall Street investor/corporations/large hospital group takeovers of hospitals, medical practices, urgent cares and many ancillary services. Stop them from turning them into widget factories focused on profit rather than high-quality, affordable health care.

Dr. Patrick Neustatter of Caroline County is the author of “Managing Your Doctor: The Smart Patient’s Guide to Getting Effective Affordable Healthcare.”

Build your health & fitness knowledge

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.


Breaking News

News Alert